Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Pflugers Arch
2015 May 01;4675:1081-90. doi: 10.1007/s00424-014-1665-1.
Show Gene links
Show Anatomy links
Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?
Kiper AK
,
Rinné S
,
Rolfes C
,
Ramírez D
,
Seebohm G
,
Netter MF
,
González W
,
Decher N
.
???displayArticle.abstract???
Atrial fibrillation and obstructive sleep apnea are responsible for significant morbidity and mortality in the industrialized world. There is a high medical need for novel drugs against both diseases, and here, Kv1.5 channels have emerged as promising drug targets. In humans, TASK-1 has an atrium-specific expression and TASK-1 is also abundantly expressed in the hypoglossal motor nucleus. We asked whether known Kv1.5 channel blockers, effective against atrial fibrillation and/or obstructive sleep apnea, modulate TASK-1 channels. Therefore, we tested Kv1.5 blockers with different chemical structures for their TASK-1 affinity, utilizing two-electrode voltage clamp (TEVC) recordings in Xenopus oocytes. Despite the low structural conservation of Kv1.5 and TASK-1 channels, we found all Kv1.5 blockers analyzed to be even more effective on TASK-1 than on Kv1.5. For instance, the half-maximal inhibitory concentration (IC50) values of AVE0118 and AVE1231 (A293) were 10- and 43-fold lower on TASK-1. Also for MSD-D, ICAGEN-4, S20951 (A1899), and S9947, the IC50 values were 1.4- to 70-fold lower than for Kv1.5. To describe this phenomenon on a molecular level, we used in silico models and identified unexpected structural similarities between the two drug binding sites. Kv1.5 blockers, like AVE0118 and AVE1231, which are promising drugs against atrial fibrillation or obstructive sleep apnea, are in fact potent TASK-1 blockers. Accordingly, block of TASK-1 channels by these compounds might contribute to the clinical effectiveness of these drugs. The higher affinity of these blockers for TASK-1 channels suggests that TASK-1 might be an unrecognized molecular target of Kv1.5 blockers effective in atrial fibrillation or obstructive sleep apnea.
Bachmann,
Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.
2001, Pubmed,
Xenbase
Bachmann,
Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.
2001,
Pubmed
,
Xenbase
Bayliss,
The TASK family: two-pore domain background K+ channels.
2003,
Pubmed
Burashnikov,
Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.
2012,
Pubmed
Burashnikov,
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
2007,
Pubmed
Campagna-Slater,
Pharmacophore screening of the protein data bank for specific binding site chemistry.
2010,
Pubmed
Christ,
Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation.
2008,
Pubmed
Cotten,
The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration.
2006,
Pubmed
,
Xenbase
Decher,
Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation.
2006,
Pubmed
,
Xenbase
Decher,
Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels.
2004,
Pubmed
,
Xenbase
Decher,
RNA editing modulates the binding of drugs and highly unsaturated fatty acids to the open pore of Kv potassium channels.
2010,
Pubmed
,
Xenbase
Dobrev,
The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation.
2005,
Pubmed
Fedida,
Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current.
1993,
Pubmed
Gardener,
Functional evidence of a role for two-pore domain potassium channels in rat mesenteric and pulmonary arteries.
2004,
Pubmed
Gögelein,
Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels.
2004,
Pubmed
,
Xenbase
Jiang,
Crystal structure and mechanism of a calcium-gated potassium channel.
2002,
Pubmed
Knobloch,
Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.
2004,
Pubmed
Knobloch,
Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
2002,
Pubmed
Kun,
Neurogenic contraction induced by the antiarrhythmic compound, AVE 0118, in rat small mesenteric arteries.
2014,
Pubmed
Li,
Evidence for two components of delayed rectifier K+ current in human ventricular myocytes.
1996,
Pubmed
Limberg,
TASK-1 channels may modulate action potential duration of human atrial cardiomyocytes.
2011,
Pubmed
,
Xenbase
Long,
Crystal structure of a mammalian voltage-dependent Shaker family K+ channel.
2005,
Pubmed
Miller,
Crystal structure of the human two-pore domain potassium channel K2P1.
2012,
Pubmed
Nattel,
Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation.
2007,
Pubmed
Pathak,
Closing in on the resting state of the Shaker K(+) channel.
2007,
Pubmed
Petric,
In vivo electrophysiological characterization of TASK-1 deficient mice.
2012,
Pubmed
Piechotta,
The pore structure and gating mechanism of K2P channels.
2011,
Pubmed
Putzke,
The acid-sensitive potassium channel TASK-1 in rat cardiac muscle.
2007,
Pubmed
,
Xenbase
Rapedius,
State-independent intracellular access of quaternary ammonium blockers to the pore of TREK-1.
2012,
Pubmed
,
Xenbase
Sali,
Comparative protein modelling by satisfaction of spatial restraints.
1993,
Pubmed
Streit,
A specific two-pore domain potassium channel blocker defines the structure of the TASK-1 open pore.
2011,
Pubmed
,
Xenbase
Strutz-Seebohm,
Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode.
2007,
Pubmed
Talley,
TASK-1, a two-pore domain K+ channel, is modulated by multiple neurotransmitters in motoneurons.
2000,
Pubmed
Tarasiuk,
The economic impact of obstructive sleep apnea.
2013,
Pubmed
Van Wagoner,
Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation.
1997,
Pubmed
Wang,
Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents.
1993,
Pubmed
Wirth,
In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231.
2007,
Pubmed
Wirth,
Sensitization of upper airway mechanoreceptors as a new pharmacologic principle to treat obstructive sleep apnea: investigations with AVE0118 in anesthetized pigs.
2013,
Pubmed
Wolf,
Impact of atrial fibrillation on mortality, stroke, and medical costs.
1998,
Pubmed
